Providing independent clinical excellence since 2005
Prediabetes should be viewed as an active cardiometabolic disease stage rather than a passive risk marker. Cardiovascular injury begins before overt diabetes, creating a critical window for intervention. Lifestyle therapy remains fundamental, while agents such as metformin, GLP-1 receptor agonists, dual incretin therapies, and SGLT2 inhibitors may help modify long-term cardiovascular risk.
Measuring your waist isn’t about shape or clothing size. It’s a simple health check that reflects harmful visceral fat around the organs. Measuring the narrowest point can miss risk. For meaningful results, waist must be measured at a fixed anatomical point and tracked consistently over time.
Medical imaging is the only reliable way to assess true body composition. Weight and smart scales cannot distinguish bone, muscle, or visceral fat. DEXA and low-dose CT provide accurate insight, while home tracking tools support the behavioural change needed to lower visceral fat and long-term cardiometabolic risk.
Santa’s famous belly is festive, but it highlights an important metabolic lesson: WHERE fat is stored matters more than how it looks. Visceral fat, hidden deep around the organs, drives inflammation and cardiometabolic risk — unlike softer, subcutaneous fat. Understanding this difference is key to real metabolic health.
If have been told your weight is high but your blood tests are “fine”, or if you are living with breathlessness or atrial fibrillation, you may be wondering how your body fat is really affecting your heart and lungs.
For patients with CKD 3b, a high-protein diet may accelerate renal decline and should be avoided. However, metabolic improvement via a moderate low-carbohydrate diet with controlled protein intake (~0.8 g/kg/day) and unsaturated fats is both feasible and safe when guided appropriately. Creatinine changes should be interpreted carefully in the context of diet, and dietary interventions should be closely monitored.
VAT is the principal metabolic culprit in cardiovascular risk. BMI—while simple—fails to capture fat distribution, muscle mass, or ageing effects. Waist-based anthropometrics, particularly waist circumference and waist-to-height ratio, more closely reflect VAT and strongly predict cardiovascular outcomes.For cardiologists, this explains why a tape measure around the waist is more valuable than a BMI calculation. Where precise measurement is required—such as in high-risk patients commencing GLP-1 therapy—DEXA and low-dose CT provide direct VAT quantification.In both prevention and clinical practice, tracking waist measurements makes far more sense than relying on BMI.
There is a wealth of evidence linking pre-diabetes, raised HbA1c, and full-blown type 2 diabetes to increasing cardiovascular risk. Lesser degrees of a pre diabetic metabolism could therefore have an important role in causing long-term atherosclerosis.
Numerous epidemiological studies have supported the hypothesis that high homocysteine levels are a risk factor for cardiovascular diseases. For example, the Framingham Heart Study demonstrated that individuals with homocysteine levels in the top fifth percentile had a nearly doubled risk of developing coronary artery disease compared to those with levels in the bottom 80 percent.
When blood sugar levels are consistently high, causing prediabetes and diabetes, the risk of conditions such as heart disease and type 2 diabetes increase in the long-term. It is easy to understand why the phenomenon of glucose spiking, where blood sugar levels surge and then fall back into the normal range after a meal, is also widely considered to be harmful.